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Shedding of endothelial protein C receptor contributes to vas-
culopathy and renal injury in lupus: In vivo and in vitro evidence.
Background. Candidate biomarkers for vasculopathy in
systemic lupus erythematosus (SLE) include circulating en-
dothelial cells and the recently identified endothelial protein
C receptor (EPCR) which, when shed, promotes a thrombotic
diathesis. This study sought correlation between plasma levels
of soluble EPCR and disease manifestation/severity, with a fo-
cus on lupus nephritis.
Methods. In 81 SLE patients (evaluated cross-sectionally and
longitudinally) and 59 healthy controls, levels of soluble EPCR
and soluble E-selectin were assessed by sandwich enzyme-
linked immunosorbent assay (ELISA), circulating endothe-
lial cells isolated by immunomagnetic separation, and EPCR
gene polymorphisms determined. Mechanisms of vascular in-
jury were addressed in vitro in human aortic endothelial cells
(HAEC) cultured in the presence and absence of interferon-c
(IFN-c).
Results. The mean level of soluble EPCR was significantly
higher in SLE patients (263 ± 13 ng/mL) than controls (174 ±
11 ng/mL) (P < 0.0001). Patients with active or past re-
nal involvement had significantly higher mean soluble EPCR
levels (306 ± 21 ng/mL) (N = 40) than patients without nephri-
tis (228 ± 14 ng/mL) (N = 41) (P = 0.0033). Mean soluble
EPCR correlated positively with serum creatinine (R = 0.3429,
P < 0.0001). The prevalence of the enhanced-shedding EPCR
polymorphism A6936G was higher in SLE (41%) (N = 27)
than controls (7%) (N = 29) (P = 0.0039). Patient and control
plasma were also interrogated for soluble E-selectin, a compara-
tor plasma marker. The results suggest that soluble E-selectin
and soluble EPCR are not equivalent end points of vasculopa-
1See Editorial by Leibovich, p. 407.
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thy and endothelial perturbation in SLE. Although in SLE
patients the absence or diminished expression of membrane
EPCR on circulating endothelial cells varied, the rare circulat-
ing endothelial cells detected in controls invariably expressed
membrane-bound EPCR. IFN-c–treated HAEC expressed less
membrane-bound EPCR [133 relative fluorescence units (rfu)]
than untreated HAEC (275 rfu); more soluble EPCR was de-
tected in IFN-c–treated (1.1 ng/106 cells) than untreated HAEC
(0.65 ng/106 cells) (P = 0.027).
Conclusion. The results obtained from this cross-
sectional/longitudinal study support the hypothesis that
the vascular dysfunction characteristic of SLE may be related
to a dramatically altered distribution of EPCR, both soluble
and membrane-bound forms.
Organ-specific manifestations in systemic lupus erythe-
matosus (SLE) are highly influenced by the inherent char-
acteristics of the vasculature. The endothelium normally
functions to thwart cell extravasation, but at inflamma-
tory sites this living barrier undergoes remarkable pheno-
typic changes such as expression of adhesion molecules,
which facilitate the passage of mononuclear cells. Diverse
studies in patients with SLE have confirmed the permis-
sive role of vascular adhesion molecules in the pathogene-
sis of vasculitis and glomerulonephritis [1–6]. Widespread
activation of the endothelium has been suggested by the
observation that even in nonlesional, nonsun-exposed
(buttock) skin from patients with active SLE, endothe-
lial expression of adhesion molecules as well as inducible
nitric oxide synthase (iNOS, NOS2) is up-regulated [7,
8]. These findings support the notion that, in SLE, the
vascular endothelium in general is “primed” for injury
by activated leukocytes and yet there is no overt in-
jury. When another factor is superimposed on widespread
priming, vascular lesions develop, contributing to specific
organ injury. For example, the deposition of immune com-
plexes in renal tissue initiates a sequence that ultimately
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involves macrophages, which are recruited to the
“primed” endothelium where they secrete inflammatory
cytokines such as interferon-c (IFN-c) [9].
A systematic study, which examines endothelial injury
in the context of known risk factors for disease, is difficult
due to the inaccessibility of the endothelium in humans.
However, circulating endothelial cells may serve as an
important biomarker since they reflect biologic events
occurring at sites where the endothelium has been acti-
vated and engaged in inflammation with subsequent loss
of functional integrity [10].
The endothelial cell protein C receptor (EPCR), a re-
cently identified cell-surface protein with important roles
in coagulation and inflammation, inhibits thrombosis by
augmenting thrombin-thrombomodulin-dependent pro-
tein C activation [11]. Additionally, the shedding of
EPCR is associated with the activation of protease-
activated receptors (PARs), a novel family of G protein–
coupled receptors that are constitutively expressed on
endothelial cells and are involved in the early recruitment
of leukocytes [12]. While the different factors that regu-
late the activity and expression of EPCR are still under in-
vestigation, recent studies have demonstrated important
molecular and genetic influences. In particular, cleavage
of the EPCR molecule near the transmembrane domain
decreases cell surface expression of EPCR and increases
plasma levels of its soluble form, soluble EPCR [13]. Sus-
ceptibility to proteolytic cleavage has been shown to be
conferred by a genetic polymorphism in exon 4 of the
EPCR gene [14]. Such shedding of membrane EPCR
would be expected to have a negative impact on endothe-
lial integrity, and on the delicate balance of coagulation
and inflammation.
Accordingly, this study was initiated to examine
whether plasma levels of soluble EPCR, representative
of a dysregulated protein C pathway, are associated with
disease manifestation and severity in SLE patients. Con-
firmation of such an association would be a first step to-
ward identification and subsequent validation of a novel
biomarker of vasculopathy. A further prediction is that
this candidate biomarker will stratify with disease man-
ifestations more likely to reflect perturbation of vascu-
lar integrity. To accomplish this goal, a cross-sectional
and longitudinal observational study of SLE patients was
conducted in which soluble EPCR levels were measured
over time and compared to levels in a healthy control
group. Both groups were also genotyped for the appro-
priate polymorphism on exon 4 of the EPCR gene. In ad-
dition, EPCR expression by circulating endothelial cells
isolated from SLE patients and healthy controls, as well
as by human aortic endothelial cells (HAEC), was evalu-
ated in vitro after stimulation with IFN-c and interleukin
(IL)-1 (cytokines important in the pathobiology of renal
disease in SLE).
METHODS
Subjects
This study and its informed consent form were ap-
proved by the Institutional Board of Research Associates
of NYU School of Medicine. Eighty-one patients who ful-
filled at least four of the American College of Rheuma-
tology criteria for the diagnosis of SLE [15] (seen in con-
sultation by the Rheumatology Service as inpatients or
outpatients at the Lupus Clinic in the Hospital for Joint
Diseases or private practice) were recruited for this study.
Patients were enrolled as a convenience sample (in order
of presentation to the physician) with the intent to rep-
resent a spectrum of disease activity and manifestations.
The patient was asked to indicate his or her intention
to receive ongoing rheumatologic care, which permitted
observational follow-up in the majority of patients (50
patients had ≥ two visits; 31 had only one visit). The fre-
quency of patient encounters and the medical manage-
ment were dictated solely by clinical need.
At the majority of visits, clinical disease activity was
assessed by the SELENA Systemic Lupus Erythemato-
sus Disease Activity Index (SLEDAI), an adaptation of
the initial SLEDAI which scores ongoing as well as re-
current or new activity [16, 17]. Medications taken and
ongoing organ involvement were recorded, and ethylene-
diaminetetraacetic acid (EDTA)–treated samples of ve-
nous blood were collected for laboratory-based studies
(see below). Patients’ available medical records were
reviewed retrospectively to capture prior organ involve-
ment that may have been quiescent during the longitu-
dinal observation period. For the 50 patients with ≥ two
visits, there was a mean of 4.2 temporally distinct vis-
its (SD 2.5 visits, range 2 to 13 visits), taking place over
a mean of 15.8 months (SD 8.8 months, range 1 to 29
months). Fifty-nine healthy subjects were recruited from
the personnel of the Hospital for Joint Diseases/NYU
School of Medicine. The characteristics of patients and
controls at the time of enrollment are summarized in
Table 1. Day 0 was defined as the day of first clinical
and laboratory evaluation of a given enrolled patient or
control.
Determination of plasma soluble EPCR and of plasma
soluble E-selectin
Plasma was collected in EDTA during the course
of a hospitalization or routine clinic visit. To avoid
venipuncture-associated circulating endothelial cells, the
blood sample used for this specific analysis was not
the first drawn. Soluble EPCR levels were determined
by a commercially available enzyme-linked immunosor-
bent assay (ELISA) (Diagnostica Stago Inc., Parsippany,
NJ, USA). The lower limit of detection of this assay is
1 ng/mL. Soluble E-selectin levels were determined by
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Table 1. Baseline characteristics of study subjects
Patients Controls
(N = 81) (N = 59)
Gender number (%)
Female 69 (85) 50 (85)
Male 12 (15) 9 (15)
Ethnicity number (%):
African American 18 (23) 6 (10)
Asian 7 (8) 17 (29)
Hispanic 46 (57) 10 (17)
White 10 (13) 26 (44)
Age years
Median 39 33
Range 19–61 1–61
SELENA-SLEDAI
Median score 2
Range 0–22
Medications taken by
patients number
Azathioprine 23
Cyclophosphamide 2
Hydroxychloroquine 56
Methotrexate 2
Mycophenalate mofetil 12
Prednisone 42
Median dosage 10 mg/day
Dosage range 5–60 mg/day
Warfarin 14
a commercially available ELISA (R&D Systems, Min-
neapolis, MN, USA). To eliminate day-to-day interassay
variability, all plasma samples from a given patient were
stored at −20◦C and assayed on the same day without
knowledge of SELENA-SLEDAI score or prior organ
involvement.
The normal range of plasma soluble EPCR was defined
as the geometric mean (+2 SD) of all values obtained over
time from the 59 control subjects.
Evaluation of EPCR polymorphism
DNA was isolated from anticoagulated blood using
the Qiagen kit (Valencia, CA, USA) according to the
manufacturer’s instructions. Polymerase chain reaction
(PCR) primers were matched to accession number
AF375468 of the EPCR gene as previously described
[14]. This method uses a PCR restriction-fragment
length polymorphism (PCR-RFLP) to genotype the
single nucleotide polymorphism (SNP) at exon 4 in each
patient. In brief, PCR reactions consisted of 50 to 100
ng DNA in 1 lL Tris EDTA, 2 lL 10 mmol/L deoxynu-
cleoside triphosphate (dNTP), 10 lL 10× Taq buffer, 3
lL 50 mmol/L MgCl2, 5 lL formamide, 10 lL 3 lmol/L 5′-
CCTACACTTCGCTGGTCCTGGGCGTCCTGGTCT
GC-3′ (EPCR F-6083), 10 lL 3 lmol/L 5′-CAAGTA
CTTTGTCCACCTCTCC-3′(EPCR R-6372), 1 lL Am-
pliTaq polymerase in a final volume of 100 lL. Cycling
conditions were as follows: 94◦C for 5 minutes; 40 cycles
at 94◦C for 1 minute, 60◦C for 1 minute, and 72◦C for
1 minute; and 72◦C for 10 minutes. When complete,
8 lL of product was digested with 1 lL restriction
enzyme buffer and 1 lL of PstI overnight at 37◦C.
Products were run on a 10% acrylamide TBE gel. The
high-shedding homozygote (G/G) has only uncut DNA.
A heterozygote has one uncut and one cut fragment at
290 and 254 bp, respectively. An individual homozygous
for A has only cut fragments. In the case of a patient who
was assigned A/G heterozygote, an uncut PCR amplified
product was inserted into a plasmid via TA cloning,
which was followed by confirmation that the population
of clones contained G and A alleles using a commercial
DNA sequencing service (GeneWiz, Rutherford, NJ,
USA).
Culturing of HAEC
HAEC (Clonetics Corp., San Diego, CA, USA) were
cultured in endothelial cell growth media (EGM-2; Clo-
netics Corp.) in 24-well tissue culture plates. Cultures
were seeded at 20% confluency on tissue culture dishes
coated with 0.1% gelatin, media changed every 2 to 3
days, passaged via trypsin/EDTA and harvested once per
week. Endothelial cells between passages 4 and 8 were
used in the experimental conditions described immedi-
ately below. Human IL-1 and IFN-c were obtained from
R&D Systems, Inc. and Sigma Chemical Co. (St. Louis,
MO, USA), respectively. In brief, HAEC were plated at
50% to 60% confluence on 6-well culture plates (Falcon)
in EGM-2 media + 10% fetal bovine serum (FBS). After
24 hours, cells were treated with either IL-1 (5 ng/mL) or
IFN-c (1 lg/mL) in the presence or absence of the met-
alloprotease inhibitor CC1000 (EMD Biosciences, Inc.,
San Diego, CA, USA) (10 nmol/L) for 24 hours. Super-
natants were collected and assayed for soluble EPCR.
Cells were collected, stained with primary antibodies
reactive to human EPCR (HEPCR 1489) [18] and an-
timouse IgG fluorescein isothiocyanate (FITC), and ana-
lyzed by FACS (Facs-Scan) (Becton Dickinson, Franklin
Lakes, NJ, USA).
Isolation and phenotypic evaluation of circulating
endothelial cells
Isolation of circulating endothelial cells was per-
formed by immunomagnetic separation after an anti-
body incubation step. Whole blood was diluted using
phosphate-buffered saline (PBS)/EDTA/bovine serum
albumin (BSA) (1:2.5) (PBS + 1 mmol/L EDTA, and
0.5% BSA), incubated for 30 minutes at 4◦C with antien-
dothelial cell monoclonal antibody P1H12 at a 1:200
dilution (16985) (Chemicon, Temecula, CA, USA) con-
jugated to magnetic beads, and separated using a Dynal
MPC-l magnetic particle concentrator (Dynal, Oslo, Nor-
way). The endothelial cell isolate was then suspended in
PBS control and affixed to glass coverslips (three cover-
slips for immunostaining) and to silica (for use in scan-
ning electron microscopy) using a cytospin technique.
Regarding the latter, these samples were fixed with 4%
paraformaldehyde (20 minutes, 22◦C), followed by three
washes in PBS, each for 5 minutes at 22◦C, and then
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stored at 4◦C. For immunostaining, circulating endothe-
lial cells applied to glass coverslips were treated with Tri-
ton X-100 and stained with anti-EPCR (HEPCR 1489)
[18]. Each glass coverslip was incubated for 30 minutes at
22◦C at 1:100 with the appropriate antibody or rabbit IgG,
followed by three washes in PBS/EDTA/BSA, each for
5 minutes at 22◦C. After removal of unbound antibody,
a secondary antibody (alkaline phosphatase–conjugated
antimouse IgG), was allowed to incubate for 30 minutes at
22◦C at 1:100. This was followed by another three washes
in PBS/EDTA/BSA, each for 5 minutes at 22◦C. Detec-
tion of circulating endothelial cells and percent positive
EPCR was achieved by sequential treatments with Gill’s
nuclear stain, and enzyme substrate, respectively. EPCR-
positive cells report red (alkaline phosphatase substrate).
Circulating endothelial cell phenotype was also assessed
based on analysis of cell morphology by scanning elec-
tron microscopy. A Leo 982 field emission digital scan-
ning electron microscope was used to measure circulating
endothelial cells size and assess surface appearance.
Statistical analysis
The Student t test for unpaired data was used to com-
pare soluble EPCR measurements between the different
groups. Statistical significance of the differences in fre-
quencies of a specific genotype (G/G, A/G, or A/A) in
patients and controls was estimated by Fisher’s exact test
with the aid of Instat software (GraphPad, San Diego,
CA, USA). P value <0.05 was considered to be signifi-
cant. In addition, Spearman’s rank correlations between
circulating endothelial cell levels and SELENA-SLEDAI
were calculated.
RESULTS
Plasma levels of soluble EPCR
As demonstrated in Figure 1, the mean level of soluble
EPCR was significantly elevated in the cohort of SLE pa-
tients compared to the healthy controls (267 ± 13 ng/mL
vs. 174 ± 11 ng/mL, respectively) (P < 0.0001). Using
soluble EPCR as a phenotype, patients were subgrouped
based on levels of soluble EPCR relative to the normal
range of plasma soluble EPCR (i.e., controls). For exam-
ple, in 23 (28%) of the 81 SLE patients (defined as group
A), soluble EPCR levels were significantly elevated
(>2 SD above control mean) (i.e., >339 ng/mL). By con-
trast, only three (5%) of 59 control subjects had elevated
soluble EPCR.
Overall, there was considerable heterogeneity in the
levels of plasma soluble EPCR among the SLE pa-
tients. Twenty-three (28%) patients had a significantly
elevated level (>339 ng/mL) on at least one visit (group
A). Moreover, when soluble EPCR was plotted at each
clinic visit in this group, values were highly variable (data
given where longitudinal measurements were available)
(Fig. 2A). For example, soluble EPCR values of one pa-
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Fig. 1. Plasma levels of soluble endothelial protein C receptor
(sEPCR). Distribution of soluble EPCR in 59 healthy controls and 81
systemic lupus erythematosus (SLE) patients. Individuals with soluble
EPCR greater than mean control + 2 SD are indicated by bold symbols.
Symbols above line indicate soluble EPCR levels greater than those of
75% of the control subjects (i.e., >200 ng/mL).
tient at four visits over a 24-month period were 267, 695,
396, 553 ng/mL (mean 475, SD 188 ng/mL). Twenty-nine
(36%) SLE patients exhibited moderately elevated levels
of soluble EPCR (201 to 339 ng/mL) (group B). The re-
maining 29 (36%) patients exhibited persistently normal
soluble EPCR levels (group C) equivalent to that seen
in the controls (≤200 ng/mL). In groups B, C, and con-
trols, the levels of soluble EPCR remained stable (Fig. 2B
to D).
Analysis of SNP of EPCR gene at nt 6936 (A → G,
associated with increased EPCR shedding)
The EPCR polymorphism A6936G (associated with
increased EPCR shedding) was analyzed in 27 SLE pa-
tients and 29 controls by a method employing PCR and
restriction enzyme digestion (Table 2). Eleven (41%) of
the 27 SLE patients were heterozygous for the G allele
(associated with increased EPCR shedding). In contrast,
only two (7%) of the controls were heterozygous for the
G allele (P = 0.0039, SLE vs. controls). As predicted,
the mean levels of soluble EPCR were elevated in both
groups with A/G genotype (357 ± 34 ng/mL for patients
and 342 ng/mL for controls) (only two of 29 controls
were A/G). Of the eight group A patients analyzed, seven
(88%) had the A/G genotype, while only one (12%) had
the A/A genotype.
Sixteen (62%) of the 27 SLE patients were homozy-
gous for the A allele. In this subgroup, the soluble EPCR
level was 225 ± 18 ng/mL, which was significantly higher
than in controls with the A/A genotype (147 ± 16 ng/mL)
(P = 0.0032, SLE vs. control). In aggregate, while the
A/G genotype was associated with high levels of soluble
EPCR, there were also patients with high levels of sol-
uble EPCR that were not accounted for by their EPCR
genotype.
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Fig. 2. Serial studies of soluble endothelial protein C receptor
(sEPCR) levels in plasma. Plasma levels of soluble EPCR were as-
sessed in systemic lupus erythematosus (SLE) patients (A to C) and
controls (D) at separate visits during an interval of 27 months. (A) Sub-
set of SLE patients with soluble EPCR levels > control mean + 2 SD
(>339 ng/mL) (group A); data are longitudinal measurements (where
available). (B) SLE patients with soluble EPCR >75% of controls but
<mean control + 2 SD (group B). (C) SLE patients with soluble EPCR
≤75% of controls (≤200 ng/mL) (group C). (D) Controls. Note: When
soluble EPCR was plotted at each clinic visit for patients in group A,
values were highly variable.
Association of plasma soluble EPCR but not EPCR
genotype with organ involvement
Clinical disease activity (as measured by SELENA-
SLEDAI) for any given patient at any point in time
was not reliably paralleled by plasma soluble EPCR (not
shown). This is not surprising, since SLEDAI does not
necessarily reflect endothelial cell injury at a given point
in time. To provide clinical data beyond a numerical score
on SELENA-SLEDAI, the specific disease manifesta-
tions present at each SLEDAI assessment are shown in
Table 3. The combined categories of stroke and venous
thrombosis were more often seen in patients in groups A
and B compared to group C, but the small sample size
precluded statistical analysis. Active renal disease at the
time of a patient encounter was most often present in
group A (group A vs. group C) (P = 0.011). The incidence
of nephritis, past or present (Table 4), was significantly
higher in group A (65%) but not in group B (55%) vs.
group C (31.0%) (P = 0.0244 and P = NS, respectively).
Patients with nephritis had significantly higher mean
levels of plasma soluble EPCR (306 ± 21 ng/mL) com-
pared to patients with no history of nephritis (228 ± 14
ng/mL) (P = 0.0033) (Table 4). Patients with nephritis
in group A (but not groups B or C) had significantly
higher mean levels of plasma soluble EPCR. For exam-
ple, the soluble EPCR of patients with nephritis (452 ±
24 ng/mL) was significantly elevated when compared to
patients with no history of nephritis (381 ± 11 ng/mL)
(P = 0.04) (Table 4).
In the patients with nephritis, the elevation of soluble
EPCR occurred even in the presence of extensive pro-
teinuria (>2 g/day). The nephritis group included a sub-
set of patients who excreted substantial amounts (>2 g)
of protein per day at some point during the observation
periods. There was also a positive correlation observed
(R = 0.3429, P < 0.0001) when levels of soluble EPCR
were compared to levels of serum creatinine. These
patient assessments (proteinuria and creatinine) reflect
impaired renal function that occurred during the obser-
vation period. However, impaired renal function would
not account for high levels of soluble EPCR in group A.
In one scenario, the assessment of plasma soluble EPCR
is an underestimation of total soluble EPCR, where renal
excretion of soluble EPCR might have been expected to
have lower plasma soluble EPCR. Although the numbers
are limited, the presence of the A/G genotype did not in-
variably associate with nephritis. Five of the 13 patients
with nephritis had the A/G genotype, whereas six of the
14 patients without nephritis also had the A/G genotype.
Plasma levels of soluble E-selectin
As shown in Figure 3, the mean level of soluble E-
selectin was significantly elevated in the cohort of SLE
patients compared to the healthy controls (58.5 ± 4.5
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Table 2. Analysis of single nucleotide polymorphism (SNP) of endothelial protein C receptor (EPCR) gene at nt 6936
Genotype Mean plasma soluble EPCR by genotype
Patients (N = 27) Controls (N = 29) Patients (N = 27) Controls (N = 29)
A/A 59% 93% 225 ± 18 ng/mLa 157 ± 13 ng/mL
A/G 41%b 7% 357 ± 34 ng/mL 342 ng/mLc
G/G 0% 0% — —
aPatients vs. controls, P = 0.0006.
bPatients vs. controls, P = 0.0145.
cOnly 2 of 29 controls were A/G.
Table 3. Clinical manifestations in systemic lupus erythematosus
(SLE) patients at each SELENA-SLEDAI assessment
Group A Group B Group C
(N = 29) (N = 46) (N = 26)
Active renal disease 12a 7 1
Arthritis 0 6 1
Cranial nerve disorder 1 0 0
Hematologic abnormality 3 3 2
Myositis 3 0 0
Mucocutaneous lesions 3 3 4
Pleurisy/pericarditis 0 0 0
Stroke 2 4 0
Vasculitis 0 0 0
Venous thrombosis 1 1 0
N is the number of SELENA-SLEDAI assessments.
aActive renal disease in group A vs. group C, P = 0.011.
Table 4. Plasma levels of soluble endothelial protein C receptor
(EPCR) in patients with and without history of nephritis
Number of patients Plasma soluble EPCR
Nephritis No nephritis Nephritis No nephritis
Total 40 41 306 ± 21 ng/mLa 228 ± 14 ng/mL
Group A 15 8 452 ± 24 ng/mLb 381 ± 11 ng/mL
Group B 16 13 249 ± 8 ng/mL 248 ± 9 ng/mL
Group C 9 20 166 ± 9 ng/mL 153 ± 5 ng/mL
aTotal patients, nephritis vs. no nephritis (P = 0.0033); nephritis 95% CI 264
to 349; no nephritis 95% CI 199 to 257.
bGroup A patients, nephritis vs. no nephritis (P = 0.04); Group A nephritis
95% CI 402–502; Group A no nephritis 95% CI 355–406.
ng/mL vs. 36.5 ± 2.5 ng/mL) (P < 0.0001). Since solu-
ble E-selectin represents a specific marker of inflamma-
tory activation of the vascular endothelium [19], patient
subgroups were analyzed for soluble E-selectin. There
was no difference in soluble E-selectin levels in patients
with nephritis versus patients without nephritis (56.5 ± 4
ng/mL vs. 63.3 ± 9 ng/mL) (P = NS). In addition, when
soluble E-selectin at each clinic visit was plotted versus
soluble EPCR, there was no correlation (R = 0.006, P =
NS) (Fig. 3B). Moreover, there were no differences in sol-
uble E-selectin in patients of EPCR group A (Fig. 1) or of
high EPCR shedding A/G genotype (Table 1) (55.5 ± 5.6
ng/mL and 57.1 ± 7 ng/mL, respectively). Taken together,
soluble E-selectin and soluble EPCR are not equivalent
end points of vasculopathy and endothelial perturbation
in SLE.
Measurements of soluble EPCR after in vitro stimulation
of HAEC
The next set of experiments were designed to ad-
dress the molecular mechanism(s) contributing to the
increased levels of soluble EPCR in SLE patients, par-
ticularly those with renal involvement, since this obser-
vation was not fully accounted for by EPCR genotyp-
ing. The approach exploited an in vitro model in which
HAEC were treated with inflammatory cytokines likely
to be important in the pathobiology of SLE. Specifically,
HAEC were cultured in the presence or absence of IFN-c
or IL-1, and in the presence and absence of a serine pro-
tease inhibitor (aprotinin) or a selective metalloprotease
inhibitor (CC1000). Treatment was followed by retrieval
of cells for assessment of expression of membrane-bound
EPCR and supernatants for evaluation of soluble EPCR.
As seen in Figure 4A, HAEC incubated with IFN-
c (100 ng/mL, 24 hours) expressed significantly less
membrane-bound EPCR than cells incubated with
medium alone (133 rfu vs. 275 rfu (N = 2) (FACS). More-
over, significantly higher levels of soluble EPCR were de-
tected in the supernatants generated from IFN-c–treated
HAEC than in supernatants from HAEC incubated with
medium alone (1102 pg/106 cells vs. 657 pg/106 cells)
(P = 0.027) (Fig. 4B). Soluble EPCR was also signif-
icantly higher in the supernatants generated following
incubation of HAEC with IL-1 (850 pg/106 cells) (P =
0.019, IL-1 vs. control) (Fig. 4B). The addition of metal-
loprotease inhibitors (CC1000) substantially reduced the
level of soluble EPCR in the supernatants generated un-
der all treatments (control, IFNc-, and IL-1). Inhibition
was 60%, 67%, and 61%, respectively. In contrast, serine
protease inhibitors (aprotinin) had no effect on shedding
of EPCR.
Evaluation of circulating endothelial cell phenotype
in SLE patients and controls
Peripheral blood samples from 28 SLE patients and
four controls were used for the simultaneous evaluations
of soluble EPCR and circulating endothelial cells (see
Methods section), which were stained for membrane-
bound EPCR. The circulating endothelial cells from
the patients were heterogeneous in their expression of
membrane-bound EPCR. Cells that did not stain for
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human aortic endothelial cells (HAEC). HAEC were incubated with or
without interferon-c (IFN-c) (100 ng/mL, 24 hours), interleukin (IL)-1
(5 ng/mL) in the absence and presence of metalloprotease inhibitors
(CC1000, 10 nM). Resting and IFN-c–treated HAEC were stained with
mouse anti-EPCR or isotype and fluorescein isothiocyanate (FITC) an-
timouse IgG. (A) Cells were analyzed by FACS. (B) Cell fluids, from the
HAEC experiment in (A), were analyzed for soluble EPCR (sEPCR)
by a sandwich enzyme-linked immunosorbent assay (ELISA) method.
membrane-bound EPCR (Fig. 5D) as well as cells that
stained positive for membrane-bound EPCR (Fig. 5E)
were evident in each of the patient isolates; the percent-
age of circulating endothelial cells that did not express
membrane-bound EPCR ranged from 6% to 70%. The
percentage of total circulating endothelial cells contain-
ing membrane-bound EPCR did not correlate to disease
activity (not shown, R = 0.2419, P = NS). In addition,
the percentage of membrane-bound EPCR-positive cir-
culating endothelial cells in patients did not correlate with
soluble EPCR levels (not shown, R = 0.1524, P = NS).
Therefore, in contrast to the in vitro studies of HAEC,
in which we observed a loss of membrane-bound EPCR
and concomitant retrieval of soluble EPCR in cell su-
pernatants, such a clearly reciprocal relationship was not
observed in vivo.
Circulating endothelial cells isolated from controls
consistently stained for membrane-bound EPCR (i.e.,
0% EPCR-negative cells) (see Fig. 5F). Circulating en-
dothelial cells stained appropriately with isotype con-
trol (Fig. 5C). Consistent with our previous observation
[10], the levels of circulating endothelial cells were signifi-
cantly higher in SLE patients than in controls (not shown,
P = 0.02) and the levels of circulating endothelial cells in
patients correlated in directly with SELENA-SLEDAI
scores (not shown, R = 0.80, P = 0.001). Evaluation by
scanning electron microscopy indicated that circulating
endothelial cells isolated from both controls and SLE pa-
tients exhibited the morphology characteristic of cells de-
rived from the endothelium (Fig. 5A and B, respectively).
The medications taken by the SLE patients (as subdi-
vided into groups A to C) are listed in Table 5. Prednisone,
hydroxychloroquine, and azathioprine were the most
widely used, while patients were less likely given war-
farin, mycophenolate mofetil, cyclophosphamide, and
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Fig. 5. Membrane-bound endothelial pro-
tein C receptor (mEPCR) in circulating
endothelial cells from systemic lupus erythe-
matosus (SLE) patients and controls. Circu-
lating endothelial cells were isolated from pe-
ripheral blood as described. Representative
stains of a patient with SLE (B to E) and con-
trols (A and F). Venous blood was drawn into
tubes with ethylenediaminetetraacetic acid
(EDTA) and studied immediately. Circulat-
ing endothelial cells were isolated by immuno-
magnetic separation using P1H12-coated iron
beads. The cell isolate was applied to sil-
ica and analyzed by scanning electron mi-
croscopy (A and B) or applied as a cytospin
to a slide, fixed, stained with isotype con-
trol (C) or with anti-EPCR (D to F) and
alkaline phosphatase–conjugated antimouse
IgG, counterstained with hematoxylin. (D) A
representative EPCR-negative circulating en-
dothelial cell from an SLE patient. (E and F)
Cells that stain positive for EPCR from SLE
patient (E) and control (F).
methotrexate. There were no significant treatment differ-
ences among the groups. However, the daily prednisone
dosage was significantly higher in groups A and B vs.
group C (P = 0.05, P = 0.0075, respectively).
DISCUSSION
The vasculature not only provides a dynamic bound-
ary between potential inflammatory mediators in the cir-
culation and the cellular components of the tissues, but
also contributes to the dynamic regulation of coagula-
tion. In SLE, barrier function may be compromised since
a hallmark of this disease is the recurrence of widespread
and diverse vascular lesions. The EPCR, poised to limit
exaggerated inflammation as well as coagulation, rep-
resents a potentially novel participant in the pathobiol-
ogy of human SLE. The results obtained from this cross-
sectional/longitudinal study support the hypothesis that
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Table 5. Medications of systemic lupus erythematosus (SLE) patients
at each visit
Group A Group B Group C
(N = 23) (N = 29) (N = 29)
Azathioprine 9 15 6
Cyclophosphamide 2 0 0
Hydroxychloroquine 19 31 22
Methotrexate 0 3 0
Mycophenalate mofetil 7 8 1
Prednisone 21 16 15
Mean daily dosea 25 ± 5 mg 29 ± 6 mg 8 ± 1 mg
Warfarin 5 12 1
N is the number of patients in each group. Number of medications reflects
each medication noted for each patient at each visit. Note: the number and
frequency of patient visits and medical management were dictated solely by
clinical need.
aMean daily dose of prednisone: group A vs. group C (P = 0.05); group B vs.
group C (P = 0.0075).
the vascular dysfunction characteristic of SLE may be re-
lated to a dramatically altered distribution of EPCR, both
soluble and membrane-bound forms, as evidenced by (1)
increased levels of soluble EPCR in patients with SLE,
particularly those with renal disease; (2) an enrichment
of the high EPCR shedding A/G genotype in SLE; (3)
decreased expression of membrane-bound EPCR and re-
ciprocal increased soluble EPCR in cytokine-stimulated
endothelial cells in vitro; and (4) variable expression of
membrane-bound EPCR on circulating endothelial cells
from SLE patients, but decreased compared to controls.
Circulating endothelial cells have been used as an
acceptable surrogate for the study of vessel wall
endothelium since they would be subjected to the same
blood-borne endothelial-activating influences as vessel
wall endothelium. Elevated levels of circulating endothe-
lial cells may be a proxy for vascular injury, as recently
demonstrated in patients with sickle cell anemia and in
patients with small vessel vasculitis [20, 21]. An increase
in tissue factor expression by these cells reflected a poten-
tial contribution to coagulation. Interestingly, we showed
decreased EPCR expression, indicating that SLE circu-
lating endothelial cells lose an anticoagulant phenotype
during the process of detachment.
EPCR, a recently described member of the protein
C anticoagulant pathway [11], accelerates formation of
activated protein C [22]. Immunohistochemistry studies
have shown that membrane-bound EPCR is expressed
primarily on endothelial cells [18]. In an atherosclerosis
biopsy study involving immunostaining of human coro-
nary artery, EPCR expression was decreased in diseased
areas of blood vessel relative to normal-appearing areas
[23]. Thrombin and IL-1 have been shown to promote the
shedding of EPCR and accumulation of soluble EPCR
[13]. Kurosawa et al [24] observed an increase in soluble
EPCR in blood obtained from SLE patients and patients
with sepsis relative to normal volunteers, suggesting that
plasma soluble EPCR may have utility as a biomarker of
blood vessel disease. A recent study demonstrated that
plasma soluble EPCR inhibits protein C activation in
vitro [25], implying that elevated levels of soluble EPCR
will promote a thrombotic diathesis.
That endothelial cells are predisposed or “primed” for
recruitment of activated leukocytes (e.g., macrophages)
in SLE may provide insight into the cellular mecha-
nism(s) contributing to EPCR shedding. In this scenario,
macrophages recruited to the endothelium via increased
expression of adhesion molecules secrete inflammatory
cytokines such as IFN-c at sites of tissue injury. A con-
sequence might be release of IFN-c into the circulation.
Of relevance, Behrens et al [26] demonstrated increased
mRNA expression of genes known to be induced by IFN-
c in peripheral mononuclear cells of SLE patients, most
notably in those with renal disease. Further support for a
role of IFN-c in renal disease was provided by Masutani
et al [9] who demonstrated high expression of this
cytokine, as well as intercellular adhesion molecule-
1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1), in kidney biopsy tissue from patients with
diffuse proliferative glomerulonephritis.
Studies in lupus mice also support the notion that the
endothelium in renal tissue is exquisitely sensitive to IFN-
c. In the MRL-lpr lupus model, treatment with anti-IFN-
c–specific monoclonal antibody or soluble IFN-c receptor
resulted in a reduction in adhesion molecules and a
significant delay in disease progression. Carvalho-Pinto
et al [27] provide evidence that MRL-lpr mice genetically
deficient in IFN-c production are capable of generating
anti-dsDNA antibodies but do not develop renal disease.
Importantly, infusion of these mice with macrophages ca-
pable of secreting IFN-c resulted in the renal injury seen
in the wild-type mice [27].
Xu et al [28] showed that thrombin effects on EPCR
shedding in the presence and absence of IL-1 were com-
pletely eliminated by the hydroxamic-based inhibitor
KD-IX-73-4. Similarly, in the present study, the metal-
loprotease inhibitor CC1000 attenuated IFN-c– and IL-
1–dependent EPCR shedding.
Further investigation is needed to establish whether
soluble EPCR is a biomarker of IFN-c–stimulated en-
dothelial injury in renal tissue, and whether components
of the pathway leading to shedding of EPCR (from IFN-c
stimulation to metalloprotease cleavage) may be fruitful
targets of therapeutic intervention.
Another mechanism for increased shedding, which
may operate in isolation or in concert with the IFN-c–
dependent pathway of soluble EPCR generation, is the
genetic predisposition conferred by the G allele at exon 4
of the EPCR gene. Recent evidence has been presented
that the A/G genotype leads to elevated soluble EPCR
in humans [14]. The mechanism by which the G allele
results in shedding of EPCR is unclear, but this SNP
codes for a modification of serine 219 to glycine. Recently,
Esmon [29] speculated that these residues are in the
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transmembrane domain, and in the altered form lead to
a glycine-glycine pair that would likely alter the trans-
membrane helix, perhaps increasing exposure to met-
alloproteases at caveolae. Furthermore, high levels of
soluble EPCR have been reported to be associated with
an increased prevalence of thrombosis although these
clinical consequences have not been uniformly verified
[14, 30]. In the study reported herein, the high-shedding
G/G genotype of EPCR was more prevalent in SLE pa-
tients than controls. However, there were individuals with
elevated soluble EPCR who did not carry the G allele.
Recent investigations of the complex and polygenic in-
heritance patterns in SLE have shown an association at
20q11 [31], the same locus that contains the EPCR gene.
Further study is needed to evaluate the relationship of
this SNP to the vasculopathy of SLE in patient subgroups.
In addition to soluble EPCR, this study also evalu-
ated circulating endothelial cells as another read out of
endothelial dysfunction. All circulating endothelial cells
from controls had membrane-bound EPCR. The detec-
tion of EPCR-negative circulating endothelial cells in
SLE patients adds further support to the notion that shed-
ding of EPCR is a component of endothelial priming
in SLE. Unexpectedly, in contrast to the in vitro stud-
ies, no direct correlation between these two endothelial-
specific markers was found (i.e., some patients had both a
high soluble EPCR and a high percentage of membrane-
bound EPCR-positive circulating endothelial cells). One
possible explanation is that soluble EPCR may be
derived from the microvasculature (e.g., renal) while
circulating endothelial cells originate from the macrovas-
culature (e.g., arteries). An alternative explanation may
be that SLE patients have both increased synthesis of
EPCR and increased shedding.
CONCLUSION
In sum, the vascular dysfunction characteristic of SLE
is associated with a dramatically altered distribution of
EPCR, both soluble and membrane-bound forms. Circu-
lating endothelial cells absent membrane-bound EPCR,
increased soluble EPCR levels, and EPCR gene polymor-
phisms may predict and/or reflect vasculopathy and renal
injury in SLE.
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